Blue Sail Medical Acquired NVTAG for 178 Million Euros

On September 23, 2019, Blue Sail Medical announced the acquisition of 100% shares of NVTAG. Blue Sail Medical has signed the share purchase agreement to acquire 51000 shares of NVTAG in the form of cash payments. The total consideration for the acquisition was approximately 17.8 million euros.

Blue Sail Medical said that the company's previous acquisition target, Biosensors International, was mainly engaged in coronary intervention, whose product line was single. NVTAG has a key product in the field of intervention of structural heart disease, the intervention aortic valve. With the rapid growth in market demand, outstanding technical level, higher competitive barriers, and added value, the product can enrich the current product portfolio of Biosensors International. 

Through this transaction, Blue Sail Medical will expand high-value medical consumables business and form strong complementary and collocation with the company's existing low-value consumables products, including medical gloves and health-protective gloves, and formally enter the field of structural heart disease treatment. Using the NVT technology platform, Blue Sail Medical will develop more products for the mitral valve and tricuspid valve involvement.

As the largest manufacturer of health-protective gloves in the world founded in 2003, Blue Sail Medical is successfully listed in Shenzhen Stock Exchange on April 02, 2010 (Stock Code 002382) and is the only listed company in domestic health-protective gloves industry.

Since 2012, Blue Sail Medical has become the leading enterprise in the industry. For broader development space and stage, it begins to carry out its own transformation and upgrading and exploration. At present, with depth development in the field of health protective industry, Blue Sail Medical takes an important position in the field of protective and medical health.